person · Reporting owner

Bacus Lisa R

Disclosed activity across 5 companies

Tapewire entity: 22581
SEC CIK: 0001577243

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cigna GroupCI · Entity 550	EVP, Chief Marketing Officer	March 01, 2019	March 06, 2019
DOUGLAS DYNAMICS, INCPLOW · Entity 5002	Director	April 29, 2026	April 30, 2026
SELECTIVE INSURANCE GROUP INCSIGI · Entity 3856	Director	May 01, 2026	May 04, 2026
TERADATA CORP /DE/TDC · Entity 1449	Director	August 14, 2026	August 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cigna Group

Report date March 01, 2019 · Filed March 06, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $.01 Par ValueSEC Table I · non-derivative	Direct	24,024	Ending reported balance After 2019-03-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-03-01 · Grant · Acquired 2,624 · Balance 24,860 F1: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2016-2018 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Row 2 · 2019-03-01 · Tax withholding · Disposed 836 · Balance 24,024 F2: Represents shares withheld to satisfy tax obligations upon vesting.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2016-2018 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals.

F2: Represents shares withheld to satisfy tax obligations upon vesting.

DOUGLAS DYNAMICS, INC

Report date April 29, 2026 · Filed April 30, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	20,242	Reported balance After 2026-04-29 transaction · row 1 1 source row Row 1 · 2026-04-29 · Grant · Acquired 2,737 · Balance 20,242

SELECTIVE INSURANCE GROUP INC

Report date May 01, 2026 · Filed May 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,552.1324	Reported balance After 2026-05-01 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-05-01 · Grant · Acquired 1,767 · Balance 8,552.1324 F1: The award of 1,767 restricted stock units will vest on May 1, 2027. F2: Includes 7.47140 dividend equivalent units. Each dividend equivalent unit is the economic equivalent of one share of Selective Insurance Group, Inc. common stock.

Filing footnotes · ownership attribution and instrument terms

F1: The award of 1,767 restricted stock units will vest on May 1, 2027.

F2: Includes 7.47140 dividend equivalent units. Each dividend equivalent unit is the economic equivalent of one share of Selective Insurance Group, Inc. common stock.

TERADATA CORP /DE/

Report date August 14, 2026 · Filed August 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	86,091	Reported balance After 2026-08-14 transaction · row 1 1 source row Row 1 · 2026-08-14 · Grant · Acquired 2,197 · Balance 86,091 F1: Award of restricted share units issued under the Director Compensation Program. The units vest in four equal quarterly installments commencing three months after the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Award of restricted share units issued under the Director Compensation Program. The units vest in four equal quarterly installments commencing three months after the grant date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cigna Holding Co

Report date December 20, 2018 · Filed December 26, 2018

Section 16 reporting ended · disclosed 2018-12-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, $.25 Par ValueSEC Table I · non-derivative	Direct	Reported balance After 2018-12-20 transaction · row 1 1 source row Row 1 · 2018-12-20 · Disposition to issuer · Disposed 21,200 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.90 · Expires 2025-02-25	Direct	Reported balance After 2018-12-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-12-20 · Disposition to issuer · Disposed 3,126 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: This option was fully vested and exercisable at the time of the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.22 · Expires 2026-03-01	Direct	Reported balance After 2018-12-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-12-20 · Disposition to issuer · Disposed 5,673 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F5: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.14 · Expires 2027-02-28	Direct	Reported balance After 2018-12-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-12-20 · Disposition to issuer · Disposed 7,711 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F6: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $197.35 · Expires 2028-02-28	Direct	Reported balance After 2018-12-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-12-20 · Disposition to issuer · Disposed 5,844 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F7: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote)

F2: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3: This option was fully vested and exercisable at the time of the Merger.

F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option.

F5: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019.

F6: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020.

F7: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 14, 2026 Filed Aug 18, 2026 21:31 UTC	TERADATA CORP /DE/ TDC · Entity 1449	GrantCommon Stock	2,197	$0.00	$0.00	Disclosure SEC source: 0001577243-26-000004 · wk-form4_1787088712.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,091 F1 · kind: Award of restricted share units issued under the Director Compensation Program. The units vest in four equal quarterly installments commencing three months after the grant date. Read SEC document
May 14, 2026 Filed May 18, 2026 20:17 UTC	TERADATA CORP /DE/ TDC · Entity 1449	GrantCommon Stock	8,790	$0.00	$0.00	Disclosure SEC source: 0001577243-26-000002 · wk-form4_1779135472.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,894 F1 · shares: Award of restricted share units issued under the Director Compensation Program. The units vest in four equal quarterly installments commencing three months after the grant date. Read SEC document
May 01, 2026 Filed May 4, 2026 20:03 UTC	SELECTIVE INSURANCE GROUP INC SIGI · Entity 3856	GrantCommon Stock	1,767	$0.00	$0.00	Disclosure SEC source: 0001225208-26-004812 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,552.1324 F1 · shares: The award of 1,767 restricted stock units will vest on May 1, 2027. F2 · balance_after: Includes 7.47140 dividend equivalent units. Each dividend equivalent unit is the economic equivalent of one share of Selective Insurance Group, Inc. common stock. Read SEC document
April 29, 2026 Filed Apr 30, 2026 20:40 UTC	DOUGLAS DYNAMICS, INC PLOW · Entity 5002	GrantCommon Stock	2,737	$0.00	$0.00	Disclosure SEC source: 0000897069-26-000985 · form4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,242 Read SEC document
February 02, 2026 Filed Feb 3, 2026 21:07 UTC	SELECTIVE INSURANCE GROUP INC SIGI · Entity 3856	PurchaseCommon Stock	600	$84.81	$50,886.00	Disclosure SEC source: 0001225208-26-001155 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,777.661 F1 · balance_after: Includes 21.00780 dividend equivalent units. Each dividend equivalent unit is the economic equivalent of one share of Selective Insurance Group, Inc. common stock. Read SEC document
May 15, 2025 Filed May 19, 2025 20:44 UTC	TERADATA CORP /DE/ TDC · Entity 1449	GrantCommon Stock	11,489	$0.00	$0.00	Disclosure SEC source: 0000816761-25-000145 · wk-form4_1747687437.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,104 F1 · kind: Award of restricted share units issued under the Director Compensation Program. The units vest in four equal quarterly installments commencing three months after the grant date. Read SEC document
May 02, 2025 Filed May 5, 2025 20:01 UTC	SELECTIVE INSURANCE GROUP INC SIGI · Entity 3856	GrantCommon Stock	1,666	$0.00	$0.00	Disclosure SEC source: 0001225208-25-004652 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,156.6532 F1 · shares: Includes the award of 1,426 restricted stock units that will vest on May 2, 2026. F2 · balance_after: Includes 18.18590 dividend equivalent units. Each dividend equivalent unit is the economic equivalent of one share of Selective Insurance Group, Inc. common stock. Read SEC document
February 18, 2025 Filed Feb 19, 2025 22:18 UTC	DOUGLAS DYNAMICS, INC PLOW · Entity 5002	GrantCommon Stock	4,394	$0.00	$0.00	Disclosure SEC source: 0000897069-25-000327 · form4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,505 Read SEC document
May 14, 2024 Filed May 15, 2024 23:34 UTC	TERADATA CORP /DE/ TDC · Entity 1449	GrantCommon Stock	6,927	$0.00	$0.00	Disclosure SEC source: 0000816761-24-000114 · wk-form4_1715816047.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,615 F1 · kind: Award of restricted share units issued under the Director Compensation Program. The units vest in four equal, quarterly installments commencing three months after the grant date. Read SEC document
May 03, 2024 Filed May 6, 2024 20:19 UTC	SELECTIVE INSURANCE GROUP INC SIGI · Entity 3856	GrantCommon Stock	1,141	$0.00	$0.00	Disclosure SEC source: 0001225208-24-005661 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,472.4673 F1 · shares: The award of 1,141 restricted stock units will vest on May 3, 2025. F2 · balance_after: Includes 13.7970 dividend equivalent units. Each dividend equivalent unit is the economic equivalent of one share of Selective Insurance Group, Inc. common stock. Read SEC document
February 13, 2024 Filed Feb 14, 2024 23:04 UTC	DOUGLAS DYNAMICS, INC PLOW · Entity 5002	GrantCommon Stock	4,142	$0.00	$0.00	Disclosure SEC source: 0000897069-24-000391 · form4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,111 Read SEC document
May 12, 2023 Filed May 12, 2023 16:17 UTC	TERADATA CORP /DE/ TDC · Entity 1449	GrantCommon Stock	6,176	$0.00	$0.00	Disclosure SEC source: 0001209191-23-028922 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,688 F1 · price: Award of restricted share units issued under the Director Compensation Program. The units vest in four equal, quarterly installments commencing three months after the grant date. Read SEC document
May 05, 2023 Filed May 8, 2023 20:15 UTC	SELECTIVE INSURANCE GROUP INC SIGI · Entity 3856	GrantCommon Stock	1,065	$0.00	$0.00	Disclosure SEC source: 0001225208-23-005571 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,317.6703 F1 · shares: The award of 1,065 restricted stock units will vest on May 5, 2024. F2 · balance_after: Includes 15.6053 dividend equivalent units. Each dividend equivalent unit is the economic equivalent of one share of Selective Insurance Group, Inc. common stock. Read SEC document
February 14, 2023 Filed Feb 16, 2023 22:19 UTC	DOUGLAS DYNAMICS, INC PLOW · Entity 5002	GrantCommon Stock	2,820	$0.00	$0.00	Disclosure SEC source: 0001567619-23-003193 · doc1.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,969 Read SEC document
May 10, 2022 Filed May 12, 2022 21:02 UTC	TERADATA CORP /DE/ TDC · Entity 1449	GrantCommon Stock	5,828	$0.00	$0.00	Disclosure SEC source: 0001209191-22-028588 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,512 F1 · price: Award of restricted share units issued under the Director Compensation Program. The units vest in four equal, quarterly installments commencing three months after the grant date. Read SEC document
May 06, 2022 Filed May 9, 2022 21:59 UTC	SELECTIVE INSURANCE GROUP INC SIGI · Entity 3856	GrantCommon Stock	1,172	$0.00	$0.00	Disclosure SEC source: 0001225208-22-006735 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,237.065 F1 · shares: The award of 1,172 restricted stock units will vest on May 6, 2023. F2 · balance_after: Includes 14.0650 dividend equivalent units. Each dividend equivalent unit is the economic equivalent of one share of Selective Insurance Group, Inc. common stock. Read SEC document
February 15, 2022 Filed Feb 17, 2022 21:54 UTC	DOUGLAS DYNAMICS, INC PLOW · Entity 5002	GrantCommon Stock	2,951	$0.00	$0.00	Disclosure SEC source: 0001567619-22-004895 · doc1.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,149 Read SEC document
May 04, 2021 Filed May 6, 2021 21:42 UTC	TERADATA CORP /DE/ TDC · Entity 1449	GrantCommon Stock	5,657	$0.00	$0.00	Disclosure SEC source: 0001209191-21-030677 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,684 F1 · price: Award of restricted share units issued under the Director Compensation Program. The units vest in four equal, quarterly installments commencing three months after the grant date. Read SEC document
April 30, 2021 Filed May 3, 2021 20:07 UTC	SELECTIVE INSURANCE GROUP INC SIGI · Entity 3856	GrantCommon Stock	1,051	$0.00	$0.00	Disclosure SEC source: 0001225208-21-007370 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,051 F1 · shares: The award of 1,051 restricted stock units will vest on April 30, 2022. Read SEC document
February 16, 2021 Filed Feb 18, 2021 15:23 UTC	DOUGLAS DYNAMICS, INC PLOW · Entity 5002	GrantCommon Stock	2,282	$0.00	$0.00	Disclosure SEC source: 0001567619-21-004375 · doc1.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,198 Read SEC document
October 28, 2020 Filed Oct 29, 2020 22:25 UTC	DOUGLAS DYNAMICS, INC PLOW · Entity 5002	GrantCommon Stock	916	$0.00	$0.00	Disclosure SEC source: 0001567619-20-018343 · doc1.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 916 Read SEC document
May 05, 2020 Filed May 7, 2020 20:52 UTC	TERADATA CORP /DE/ TDC · Entity 1449	GrantCommon Stock	10,913	$0.00	$0.00	Disclosure SEC source: 0001209191-20-027734 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,027 F1 · price: Award of restricted share units issued under the Director Compensation Program. The units vest in four equal, quarterly installments commencing three months after the grant date. Read SEC document
April 30, 2019 Filed May 2, 2019 22:13 UTC	TERADATA CORP /DE/ TDC · Entity 1449	GrantCommon Stock	5,628	$0.00	$0.00	Disclosure SEC source: 0001209191-19-027090 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,114 F1 · price: Award of restricted share units issued under the Director Compensation Program. The units vest in four equal, quarterly installments commencing three months after the grant date. Read SEC document
March 14, 2019 Filed Mar 15, 2019 21:21 UTC	TERADATA CORP /DE/ TDC · Entity 1449	SaleCommon Stock	12,000	$48.04	$576,456.00	Disclosure SEC source: 0001209191-19-019763 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,486 F1 · price: The price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.98 to $48.13. The reporting person has provided to the issuer and will provide any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
March 01, 2019 Filed Mar 6, 2019 02:24 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	836	$177.85	$148,682.60	Disclosure SEC source: 0001225208-19-004745 · doc4.xml · nonDerivative · entry 2 Bacus Lisa R · CIK 0001577243 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,024 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting. Read SEC document
March 01, 2019 Filed Mar 6, 2019 02:24 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	2,624	$0.00	$0.00	Disclosure SEC source: 0001225208-19-004745 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,860 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2016-2018 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
February 27, 2019 Filed Mar 2, 2019 01:22 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	3,578	$0.00 Strike: $183.44	$0.00	Disclosure SEC source: 0001225208-19-004241 · doc4.xml · derivative · entry 2 Bacus Lisa R · CIK 0001577243 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,578 Underlying: Common Stock, $.01 Par Value · 3,578 shares Expires 2029-02-27 F2 · derivative.exercise_date: This option vests in three equal annual installments beginning February 27, 2020. Read SEC document
February 27, 2019 Filed Mar 2, 2019 01:22 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	1,036	$0.00	$0.00	Disclosure SEC source: 0001225208-19-004241 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,236 F1 · shares: These restricted shares vest in three equal annual installments beginning February 27, 2020. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:41 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	5,844	Not disclosed Strike: $197.35	Not disclosed	Disclosure SEC source: 0001567619-18-008648 · doc1.xml · derivative · entry 5 Bacus Lisa R · CIK 0001577243 · EVP, Chf Marketing & Cust Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 5,844 shares Expires 2028-02-28 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F7 · derivative.exercise_date: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:41 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	7,711	Not disclosed Strike: $149.14	Not disclosed	Disclosure SEC source: 0001567619-18-008648 · doc1.xml · derivative · entry 4 Bacus Lisa R · CIK 0001577243 · EVP, Chf Marketing & Cust Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 7,711 shares Expires 2027-02-28 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F6 · derivative.exercise_date: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:41 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	5,673	Not disclosed Strike: $139.22	Not disclosed	Disclosure SEC source: 0001567619-18-008648 · doc1.xml · derivative · entry 3 Bacus Lisa R · CIK 0001577243 · EVP, Chf Marketing & Cust Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 5,673 shares Expires 2026-03-01 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F5 · derivative.exercise_date: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:41 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	3,126	Not disclosed Strike: $120.90	Not disclosed	Disclosure SEC source: 0001567619-18-008648 · doc1.xml · derivative · entry 2 Bacus Lisa R · CIK 0001577243 · EVP, Chf Marketing & Cust Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 3,126 shares Expires 2025-02-25 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:41 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerCommon Stock, $.25 Par Value	21,200	$0.00	$0.00	Disclosure SEC source: 0001567619-18-008648 · doc1.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · EVP, Chf Marketing & Cust Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F1 · price: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. Read SEC document
December 20, 2018 Filed Dec 27, 2018 00:11 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	5,844	Not disclosed Strike: $197.35	Not disclosed	Disclosure SEC source: 0001567619-18-008693 · doc1.xml · derivative · entry 5 Bacus Lisa R · CIK 0001577243 · EVP, Chief Mktg Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,844 Underlying: Common Stock, $0.01 Par Value · 5,844 shares Expires 2028-02-28 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F7 · derivative.exercise_date: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms. Read SEC document
December 20, 2018 Filed Dec 27, 2018 00:11 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	7,711	Not disclosed Strike: $149.14	Not disclosed	Disclosure SEC source: 0001567619-18-008693 · doc1.xml · derivative · entry 4 Bacus Lisa R · CIK 0001577243 · EVP, Chief Mktg Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,711 Underlying: Common Stock, $0.01 Par Value · 7,711 shares Expires 2027-02-28 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F6 · derivative.exercise_date: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020. Read SEC document
December 20, 2018 Filed Dec 27, 2018 00:11 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	5,673	Not disclosed Strike: $139.22	Not disclosed	Disclosure SEC source: 0001567619-18-008693 · doc1.xml · derivative · entry 3 Bacus Lisa R · CIK 0001577243 · EVP, Chief Mktg Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,673 Underlying: Common Stock, $0.01 Par Value · 5,673 shares Expires 2026-03-01 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F5 · derivative.exercise_date: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019. Read SEC document
December 20, 2018 Filed Dec 27, 2018 00:11 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	3,126	Not disclosed Strike: $120.90	Not disclosed	Disclosure SEC source: 0001567619-18-008693 · doc1.xml · derivative · entry 2 Bacus Lisa R · CIK 0001577243 · EVP, Chief Mktg Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,126 Underlying: Common Stock, $0.01 Par Value · 3,126 shares Expires 2025-02-25 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document
December 20, 2018 Filed Dec 27, 2018 00:11 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $0.01 Par Value	21,200	$0.00	$0.00	Disclosure SEC source: 0001567619-18-008693 · doc1.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · EVP, Chief Mktg Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,200 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F1 · price: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. Read SEC document
April 17, 2018 Filed Apr 19, 2018 20:22 UTC	TERADATA CORP /DE/ TDC · Entity 1449	GrantCommon Stock	6,216	$0.00	$0.00	Disclosure SEC source: 0001209191-18-025557 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,486 F1 · price: Award of restricted share units issued under the Director Compensation Program. The units vest in four equal, quarterly installments commencing three months after the grant date. Read SEC document
March 02, 2018 Filed Mar 6, 2018 18:40 UTC	Cigna Holding Co CI · Entity 161580	Tax withholdingCommon Stock, $.25 Par Value	1,248	$192.44	$240,165.12	Disclosure SEC source: 0001225208-18-005493 · doc4.xml · nonDerivative · entry 2 Bacus Lisa R · CIK 0001577243 · EVP, Chf Marketing & Cust Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,200 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting. Read SEC document
March 02, 2018 Filed Mar 6, 2018 18:40 UTC	Cigna Holding Co CI · Entity 161580	GrantCommon Stock, $.25 Par Value	3,947	$0.00	$0.00	Disclosure SEC source: 0001225208-18-005493 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · EVP, Chf Marketing & Cust Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,448 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2015-2017 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
February 28, 2018 Filed Mar 2, 2018 17:26 UTC	Cigna Holding Co CI · Entity 161580	GrantEmployee Stock Option (Right to Buy) · Derivative	5,844	$0.00 Strike: $197.35	$0.00	Disclosure SEC source: 0001225208-18-005174 · doc4.xml · derivative · entry 1 Bacus Lisa R · CIK 0001577243 · EVP, Chf Marketing & Cust Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,844 Underlying: Common Stock, $.25 Par Value · 5,844 shares Expires 2028-02-28 F1 · derivative.exercise_date: This option vests in three equal annual installments beginning February 28, 2019. Read SEC document
August 16, 2017 Filed Aug 17, 2017 17:11 UTC	Cigna Holding Co CI · Entity 161580	SaleCommon Stock, $.25 Par Value	2,236	$179.95	$402,365.96	Disclosure SEC source: 0001225208-17-014140 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · EVP, Chf Marketing & Cust Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,501 Read SEC document
May 24, 2017 Filed May 26, 2017 16:14 UTC	Cigna Holding Co CI · Entity 161580	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	2,836	$0.00 Strike: $139.22	$0.00	Disclosure SEC source: 0001225208-17-010488 · doc4.xml · derivative · entry 7 Bacus Lisa R · CIK 0001577243 · EVP, Chf Marketing & Cust Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,673 Underlying: Common Stock, $.25 Par Value · 2,836 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vests in three equal annual installments. The first installment became exercisable on March 1, 2017, and the next two installments become exercisable on March 1, 2018 and March 1, 2019. Read SEC document
May 24, 2017 Filed May 26, 2017 16:14 UTC	Cigna Holding Co CI · Entity 161580	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	4,603	$0.00 Strike: $78.04	$0.00	Disclosure SEC source: 0001225208-17-010488 · doc4.xml · derivative · entry 6 Bacus Lisa R · CIK 0001577243 · EVP, Chf Marketing & Cust Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 4,603 shares Expires 2024-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on February 26, 2014. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
May 24, 2017 Filed May 26, 2017 16:14 UTC	Cigna Holding Co CI · Entity 161580	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	6,252	$0.00 Strike: $120.90	$0.00	Disclosure SEC source: 0001225208-17-010488 · doc4.xml · derivative · entry 5 Bacus Lisa R · CIK 0001577243 · EVP, Chf Marketing & Cust Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,126 Underlying: Common Stock, $.25 Par Value · 6,252 shares Expires 2025-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vests in three equal annual installments. The first installment became exercisable on February 25, 2016, the second installment became exercisable on February 25, 2017, and the last installment becomes exercisable on February 25, 2018. Read SEC document
May 24, 2017 Filed May 26, 2017 16:14 UTC	Cigna Holding Co CI · Entity 161580	SaleCommon Stock, $.25 Par Value	11,455	$161.57	$1,850,768.31	Disclosure SEC source: 0001225208-17-010488 · doc4.xml · nonDerivative · entry 4 Bacus Lisa R · CIK 0001577243 · EVP, Chf Marketing & Cust Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,737 F1 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $161.5607 to $161.60 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
May 24, 2017 Filed May 26, 2017 16:14 UTC	Cigna Holding Co CI · Entity 161580	Exercise / conversionCommon Stock, $.25 Par Value	2,836	$139.22	$394,827.92	Disclosure SEC source: 0001225208-17-010488 · doc4.xml · nonDerivative · entry 3 Bacus Lisa R · CIK 0001577243 · EVP, Chf Marketing & Cust Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 24, 2017 Filed May 26, 2017 16:14 UTC	Cigna Holding Co CI · Entity 161580	Exercise / conversionCommon Stock, $.25 Par Value	4,603	$78.04	$359,195.11	Disclosure SEC source: 0001225208-17-010488 · doc4.xml · nonDerivative · entry 2 Bacus Lisa R · CIK 0001577243 · EVP, Chf Marketing & Cust Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 24, 2017 Filed May 26, 2017 16:14 UTC	Cigna Holding Co CI · Entity 161580	Exercise / conversionCommon Stock, $.25 Par Value	6,252	$120.90	$755,835.54	Disclosure SEC source: 0001225208-17-010488 · doc4.xml · nonDerivative · entry 1 Bacus Lisa R · CIK 0001577243 · EVP, Chf Marketing & Cust Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.